Security Snapshot

Replimune Group, Inc. - Common Stock, $0.001 par value (REPL) Institutional Ownership

CUSIP: 76029N106

13F Institutional Holders and Ownership History from Q3 2018 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

162

Shares (Excl. Options)

79,746,267

Price

$9.72

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
REPL on Nasdaq
Shares outstanding
82,661,978
Price per share
$4.76
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
79,746,267
Total reported value
$775,188,444
% of total 13F portfolios
0%
Share change
-3,647,213
Value change
+$17,935,628
Number of holders
162
Price from insider filings
$4.76
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • REPL - Replimune Group, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 76029N106.
  • 162 institutions reported positions in Q4 2025.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 162 to 106 between Q4 2025 and Q1 2026.
  • Reported value moved from $775,188,444 to $172,513,701.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 162 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 76029N106?
CUSIP 76029N106 identifies REPL - Replimune Group, Inc. - Common Stock, $0.001 par value in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Replimune Group, Inc. - Common Stock, $0.001 par value (REPL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 14% $99,960,291 11,045,336 Baker Bros. Advisors LP 07 Mar 2025
RTW INVESTMENTS, LP 8.9% +8.8% $35,018,920 +$4,575,236 7,356,916 +15% RTW Investments, LP 31 Mar 2026
SUVRETTA CAPITAL MANAGEMENT, LLC 5.1% $20,095,939 4,221,836 Suvretta Capital Management, LLC 31 Mar 2026
Point72 Asset Management, L.P. 4.7% -17% $15,209,289 -$3,488,586 3,629,902 -19% Point72 Asset Management, L.P. 30 Sep 2025
VANGUARD GROUP INC 4.8% $32,542,424 3,595,848 The Vanguard Group 31 Dec 2024
Forbion Capital Fund III Cooperatief U.A. 3.5% -43% $22,579,279 -$11,344,215 2,808,368 -33% Forbion Capital Fund III Cooperatief U.A. 31 Dec 2025
Redmile Group, LLC 0.7% -95% $2,245,077 -$18,279,751 535,818 -89% Redmile Group, LLC 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 0.2% -95% $751,913 -$38,788,250 157,965 -98% T. Rowe Price Associates, Inc. 30 Apr 2026

As of 31 Dec 2025, 162 institutional investors reported holding 79,746,267 shares of Replimune Group, Inc. - Common Stock, $0.001 par value (REPL). This represents 96% of the company’s total 82,661,978 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Replimune Group, Inc. - Common Stock, $0.001 par value (REPL) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 13% 11,045,336 0% 0.63% $107,360,666
PRICE T ROWE ASSOCIATES INC /MD/ 10% 8,262,296 -0.53% 0.01% $80,310,000
RTW INVESTMENTS, LP 8.6% 7,140,352 +12% 0.7% $69,404,221
BlackRock, Inc. 7.3% 6,069,633 +5.1% 0% $58,996,834
VANGUARD GROUP INC 4.6% 3,776,198 +8.5% 0% $36,704,645
STATE STREET CORP 4.5% 3,693,107 +26% 0% $35,897,000
FMR LLC 3.6% 2,981,580 +119% 0% $28,980,955
FCPM III SERVICES B.V. 3.4% 2,808,368 -32% 3.6% $27,297,337
D. E. Shaw & Co., Inc. 3.1% 2,575,042 +538% 0.02% $25,029,408
TORONTO DOMINION BANK 2.7% 2,229,527 +62% 0.04% $21,671,002
Erste Asset Management GmbH 2.6% 2,120,000 +30% 0.17% $20,619,200
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.2% 1,807,368 0.03% $17,567,617
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,750,194 +3.2% 0% $17,015,933
Commodore Capital LP 1.7% 1,425,000 0.92% $13,851,000
Rosalind Advisors, Inc. 1.7% 1,410,497 5.3% $13,710,031
ADAR1 Capital Management, LLC 1.5% 1,241,322 +27% 0.9% $12,065,650
DIMENSIONAL FUND ADVISORS LP 1.4% 1,119,357 -11% 0% $10,880,742
Redmile Group, LLC 1.3% 1,099,756 +105% 0.79% $10,689,628
JPMORGAN CHASE & CO 1.1% 925,173 +2334% 0% $8,992,681
MILLENNIUM MANAGEMENT LLC 1% 834,562 -48% 0.01% $8,111,943
MORGAN STANLEY 0.99% 814,888 -41% 0% $7,920,720
Boxer Capital Management, LLC 0.91% 750,000 -29% 1.6% $7,290,000
Jefferies Financial Group Inc. 0.86% 714,226 0.06% $6,942,277
GOLDMAN SACHS GROUP INC 0.8% 658,096 -42% 0% $6,396,693
Invesco Ltd. 0.74% 613,015 +297% 0% $5,958,506

Institutional Holders of Replimune Group, Inc. - Common Stock, $0.001 par value (REPL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 22,722,723 $172,513,701 -$9,980,873 $7.65 106
2025 Q4 79,746,267 $775,188,444 +$17,935,628 $9.72 162
2025 Q3 82,882,164 $347,530,533 -$49,961,720 $4.19 161
2025 Q2 80,960,067 $752,124,138 -$9,722,609 $9.29 173
2025 Q1 81,976,905 $799,308,276 +$36,933,791 $9.75 165
2024 Q4 77,881,821 $943,217,348 +$80,774,805 $12.11 155
2024 Q3 69,947,896 $766,692,674 -$7,687,757 $10.96 143
2024 Q2 70,902,356 $638,102,295 +$37,351,096 $9.00 148
2024 Q1 67,014,350 $547,213,173 +$8,620,113 $8.17 147
2023 Q4 66,033,045 $556,812,735 -$40,625,538 $8.43 138
2023 Q3 56,812,005 $970,921,194 +$32,501,979 $17.11 126
2023 Q2 54,593,396 $1,267,069,422 +$26,630,495 $23.22 139
2023 Q1 53,816,654 $948,994,808 +$90,895,078 $17.66 138
2022 Q4 48,204,772 $1,310,877,449 +$189,427,869 $27.20 135
2022 Q3 40,775,249 $704,191,848 -$8,659,480 $17.27 103
2022 Q2 39,999,317 $700,208,199 +$17,983,844 $17.48 98
2022 Q1 39,119,622 $665,006,692 -$35,451,893 $16.98 104
2021 Q4 38,825,604 $1,050,822,879 +$5,595,187 $27.10 97
2021 Q3 35,350,579 $1,048,056,990 +$5,527,419 $29.64 99
2021 Q2 34,863,218 $1,338,855,937 -$5,476,278 $38.42 109
2021 Q1 34,665,378 $1,057,669,955 +$1,013,258 $30.51 106
2020 Q4 34,484,345 $1,315,869,430 +$362,197,042 $38.15 112
2020 Q3 26,602,669 $611,849,920 +$25,676,805 $23.02 78
2020 Q2 25,420,897 $630,933,046 +$87,691,348 $24.85 75
2020 Q1 22,171,093 $220,779,588 -$470,574 $9.97 56
2019 Q4 22,018,833 $315,719,677 +$48,171,940 $14.35 61
2019 Q3 18,572,485 $257,907,605 -$14,772,415 $13.90 51
2019 Q2 19,565,712 $286,574,644 +$6,757,973 $14.66 53
2019 Q1 19,131,429 $291,385,593 +$17,749,806 $15.22 53
2018 Q4 18,156,099 $181,563,000 +$1,489,969 $10.00 50
2018 Q3 17,925,571 $288,599,000 +$288,599,000 $16.10 54
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .